Why was a meta-analysis needed?

Gallbladder events are too infrequent for a single weight-loss trial to detect a difference. Pooling produces enough events to estimate one.

Is pooled randomised data better than a cohort?

For this question, yes on one axis — randomisation within each trial removes confounding by indication, which cohort studies cannot.

How should a relative increase be read?

Against the absolute baseline rate. A relative increase in an infrequent event is still infrequent, and the relative figure alone conveys little.

GLP-1 & Incretin Science

What the Meta-Analysis Established

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

He and colleagues published a systematic review and meta-analysis in JAMA Internal Medicine in 2022 examining the association of GLP-1 receptor agonist use with risk of gallbladder and biliary diseases — the pooled analysis that turned scattered trial observations into an estimate.

Key facts

Study: He 2022, JAMA Intern Med (PMID 35344001)
Design: Systematic review and meta-analysis
Outcome: Gallbladder and biliary diseases
Why pooled: Events too infrequent in single trials
Mechanism identified: CCK suppression (Rehfeld 2018)
Tirzepatide-specific: Zeng 2023 (PMID 37908750)

Why individual trials could not answer this

Gallbladder events occur in a small percentage of participants. A trial powered to detect a difference in weight reduction is not powered to detect a difference in an outcome affecting a few per cent, so individual trials produce numbers too small to interpret — a handful of events in each arm, consistent with almost anything.

What pooling achieves

Combining events across many randomised trials produces enough of them to estimate a difference with usable precision, while retaining randomisation. That is the key advantage over an observational cohort: confounding by indication does not arise, because assignment was random within each contributing trial.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why this signal was noticed at all

Because it appeared consistently. A scattering of gallbladder events across many trials of the same drug class, in the same direction, is the pattern that prompts a formal pooled analysis. Isolated events in one trial would not have.

The tirzepatide-specific question

Zeng and colleagues addressed pancreatitis and gallbladder or biliary disease with tirzepatide specifically in a systematic review and meta-analysis in Frontiers in Endocrinology in 2023. Compound-specific analyses matter because this class has already proven non-uniform — the oral contraceptive interaction is tirzepatide-specific and not shared by the pure GLP-1 agonists.

How to read a pooled safety estimate

As a relative measure attached to an absolute baseline. A relative increase in an infrequent event remains an infrequent event, and a relative figure quoted without the underlying rate conveys almost nothing about magnitude. This is the most common way safety meta-analyses are misreported.

What it does not describe

Anything supplied on this site. These analyses pool randomised trials of licensed and investigational medicines administered under clinical supervision. No research material is a GLP-1 receptor agonist or is covered by any of this evidence.

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why was a meta-analysis needed?: Gallbladder events are too infrequent for a single weight-loss trial to detect a difference. Pooling produces enough events to estimate one.
Is pooled randomised data better than a cohort?: For this question, yes on one axis — randomisation within each trial removes confounding by indication, which cohort studies cannot.
How should a relative increase be read?: Against the absolute baseline rate. A relative increase in an infrequent event is still infrequent, and the relative figure alone conveys little.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum